Ethyl 2-chloroacetoacetate

We are Ethyl 2-chloroacetoacetate CAS:609-15-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Ethyl 2-chloroacetoacetate
CAS.NO:609-15-4
Synonyms:Ethyl 2-chloroacetoacetate
Butanoic acid, 2-chloro-3-oxo-, ethyl ester
Ethyl 4-chloro-3-oxobutanoate
2-Chloroacetoacetic acid ethyl ester
ethyl 2-chloro-3-oxobutanoate
 
Physical and Chemical Properties:
Density 1.2±0.1 g/cm3
Boiling Point 225.5±0.0 °C at 760 mmHg
Melting Point -80 °C
Molecular Formula C6H9ClO3
Molecular Weight 164.587
Flash Point 50.0±0.0 °C
 
Specification:
Appearance:Colorless clear liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Febuxostat(CAS:144060-53-7).

Ethyl 2-chloroacetoacetate


Related News: Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.1,4-diclorobutano CAS:110-56-5 The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations.Hemisulfato de 3-aminofenol CAS:68239-81-6 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?3-fluoro-1-propanol acetate This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added.

Related Products
Product Name
7-oxo-7-phenylheptanoic acid View Details
dUMP View Details
[2-Oxo-3-[3-(trifluoromethyl)phenoxy]propyl]phosphonic Acid Dimethyl Ester View Details
4′-ethynyl-2-fluoro-2′-deoxyadenosine manufacturer N-(2-chloropyrimidin-4-yl)-2,3-dimethylindazol-6-amine manufacturer 5-Bromo-3-(Trifluoromethyl)-2-Pyridinecarbonitrile manufacturer Iodotrimethylsilane manufacturer (2S)-beta-Alanyl-L-prolyl-2,4-diamino-N-(phenylmethyl)butanamide acetate manufacturer